These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

309 related items for PubMed ID: 22890512

  • 1. Long-term eculizumab improves clinical outcomes in atypical hemolytic uremic syndrome.
    Vilalta R, Lara E, Madrid A, Chocron S, Muñoz M, Casquero A, Nieto J.
    Pediatr Nephrol; 2012 Dec; 27(12):2323-6. PubMed ID: 22890512
    [Abstract] [Full Text] [Related]

  • 2. Eculizumab in atypical hemolytic uremic syndrome: long-term clinical course and histological findings.
    Tschumi S, Gugger M, Bucher BS, Riedl M, Simonetti GD.
    Pediatr Nephrol; 2011 Nov; 26(11):2085-8. PubMed ID: 21877169
    [Abstract] [Full Text] [Related]

  • 3. Terminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial.
    Fakhouri F, Hourmant M, Campistol JM, Cataland SR, Espinosa M, Gaber AO, Menne J, Minetti EE, Provôt F, Rondeau E, Ruggenenti P, Weekers LE, Ogawa M, Bedrosian CL, Legendre CM.
    Am J Kidney Dis; 2016 Jul; 68(1):84-93. PubMed ID: 27012908
    [Abstract] [Full Text] [Related]

  • 4. Renal recovery with eculizumab in atypical hemolytic uremic syndrome following prolonged dialysis.
    Povey H, Vundru R, Junglee N, Jibani M.
    Clin Nephrol; 2014 Nov; 82(5):326-31. PubMed ID: 23557793
    [Abstract] [Full Text] [Related]

  • 5. Safety and effectiveness of eculizumab for pediatric patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance.
    Ito S, Hidaka Y, Inoue N, Kaname S, Kato H, Matsumoto M, Miyakawa Y, Mizuno M, Okada H, Shimono A, Matsuda T, Maruyama S, Fujimura Y, Nangaku M, Kagami S.
    Clin Exp Nephrol; 2019 Jan; 23(1):112-121. PubMed ID: 30039480
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Eculizumab as rescue therapy for atypical hemolytic uremic syndrome with normal platelet count.
    Dorresteijn EM, van de Kar NC, Cransberg K.
    Pediatr Nephrol; 2012 Jul; 27(7):1193-5. PubMed ID: 22399074
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Efficacy of eculizumab in a patient with factor-H-associated atypical hemolytic uremic syndrome.
    Lapeyraque AL, Frémeaux-Bacchi V, Robitaille P.
    Pediatr Nephrol; 2011 Apr; 26(4):621-4. PubMed ID: 21161283
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Neurologic involvement in atypical hemolytic uremic syndrome and successful treatment with eculizumab.
    Gulleroglu K, Fidan K, Hançer VS, Bayrakci U, Baskin E, Soylemezoglu O.
    Pediatr Nephrol; 2013 May; 28(5):827-30. PubMed ID: 23389237
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Eculizumab: a review of its use in atypical haemolytic uraemic syndrome.
    Keating GM.
    Drugs; 2013 Dec; 73(18):2053-66. PubMed ID: 24249647
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.